InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition. With our long history in the industry, we provide more than 6,000 research publications. Research title with ★ indicates InBody recommended paper.

Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism

M. Chikugo, et al.
Used Parameters : BMI, SMM, SMI, BFM, BCM

Publication Year : 2018

Country : Japan

Journal : The Journal of Medical Investigation

Tofacitinib is the first Janus Kinase (JAK) inhibitor to treat moderately to severely active RA. In this study, we investigated whether the effect of tofacitinib have any effects on body composition in mice and female patients with RA. Female C57BL/6 mice fed with a high-fat diet were treated with 30 mg/kg/day tofacitinib or vehicle for 70 days. Following treatment, trunk muscle, subcutaneous fat, and visceral fats were measured using X-ray computed tomography CT scan. Glucose tolerance and insulin sensitivity were assessed. In female RA …
Full text